MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
Status:
Completed
Trial end date:
2020-12-07
Target enrollment:
Participant gender:
Summary
This study will be conducted in different centres and will study adult patients with
Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study
treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase
(Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the
achievement of an early negative minimal residual disease (MRD) status. The MRD study
supports a risk/MRD-oriented final consolidation phase.